| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Doherty James J. | President and CDO | C/O ACUMEN PHARMACEUTICALS, INC., 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON | /s/ Derek Meisner, Attorney-in-Fact | 09 Jan 2026 | 0002009718 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABOS | Common Stock | Sale | $3,379 | -1,700 | -2.7% | $1.99 | 60,500 | 07 Jan 2026 | Direct | F1, F2, F3 |
| transaction | ABOS | Common Stock | Sale | $11,769 | -6,467 | -11% | $1.82 | 54,033 | 08 Jan 2026 | Direct | F1, F4 |
| Id | Content |
|---|---|
| F1 | Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. |
| F2 | The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9550 to $2.0200. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | Number of securities reported as beneficially owned by Mr. Doherty following the reported transaction reflects the correction of a typographical error in the Form 4 report filed January 7, 2025, which overreported the number of RSUs granted to Mr. Doherty on January 6, 2025, by 400 shares. |
| F4 | The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |